RMS

EQS-News: Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, March 13, 2024

The highly encouraging results demonstrated clear separation from placebo in serum neurofilament light chain (NfL) levels in patients with progressive multiple sclerosis (PMS).

Key Points: 
  • The highly encouraging results demonstrated clear separation from placebo in serum neurofilament light chain (NfL) levels in patients with progressive multiple sclerosis (PMS).
  • The results demonstrated meaningful improvements over placebo in four key dimensions of celiac disease pathophysiology: histology, disease symptoms, biomarkers and nutrient absorption.
  • Registrants will receive a confirmation email containing a link for online participation or a telephone number for dial in access.
  • An archived replay of the webcast will be available approximately one hour after completion on Immunic’s website at: ir.imux.com/events-and-presentations .

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting

Retrieved on: 
Friday, March 8, 2024

NEW YORK, March 08, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming American Academy of Neurology 2024 annual meeting, being held April 13 - 18, 2024, in Dever, Colorado.

Key Points: 
  • NEW YORK, March 08, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming American Academy of Neurology 2024 annual meeting, being held April 13 - 18, 2024, in Dever, Colorado.
  • Abstracts are now available online and can be accessed on the AAN meeting website at https://www.aan.com/msa/Public/Events/Index/49 .
  • Details of the upcoming presentations are outlined below.
  • Lead Author: Stephen Krieger, MD - The Corinne Goldsmith Dickinson Center for MS, The Mount Sinai Hospital NY, NY
    Lead Author: Derrick Robertson, MD - University of South Florida (USF) Morsani College of Medicine in Tampa, Florida
    Lead Author: Derrick Robertson, MD - University of South Florida (USF) Morsani College of Medicine in Tampa, Florida
    Following the presentations, the data presented will be available on the Publications page, located within the Pipeline section, of the Company’s website at www.tgtherapeutics.com/publications.cfm .

TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

Retrieved on: 
Friday, March 1, 2024

NEW YORK, March 01, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data from the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, being held in West Palm Beach, Florida.

Key Points: 
  • NEW YORK, March 01, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data from the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, being held in West Palm Beach, Florida.
  • Links to each presentation are included below.
  • Michael S. Weiss, Chief Executive Officer and Chairman of TG Therapeutics stated, “We were pleased to present updated data from the ENHANCE trail evaluating patients switching from a current CD20 to BRIUMVI.
  • It was encouraging to see that patients who switched to one-hour BRIUMVI experienced a manageable safety and tolerability profile.

TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2023 Financial Results

Retrieved on: 
Wednesday, February 28, 2024

NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) --  TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the fourth quarter and year ended December 31, 2023, along with recent company developments.Michael S. Weiss, the Company's Chairman and Chief Executive Officer, stated, “2023 was an exciting year of execution for TG, which we believe has set the stage for a successful 2024. The BRIUMVI launch exceeded our expectations, and we ended the year with approximately $89 million in U.S. net revenue and provided a BRIUMVI U.S. net revenue target of $220 - $260 million for 2024. Further executing on our corporate objectives in 2023, we presented the first data from our ENHANCE Phase 3 b trial evaluating patients who switch from prior CD20 therapy to BRIUMVI, and recently broadened our BRIUMVI clinical efforts to include subcutaneous development and potential expansion beyond MS. We look forward to sharing additional developments from these efforts throughout the year, as well as advancing our recent pipeline addition, azer-cel, an allogeneic CAR T into clinical development in autoimmune disease.” Mr. Weiss continued, “We were also pleased to see our ex-US partner, Neuraxpharm, commence the launch of BRIUMVI in Europe this week. As the year progresses, we look forward to providing continued updates on our launch of BRIUMVI in the U.S. and sharing data updates throughout the year at major medical meetings.”

Key Points: 
  • Fourth quarter and full year 2023 BRIUMVI U.S. net revenue of approximately $40 million and $89 million, respectively
    Conference call to be held today, February 28, 2024, at 8:30 AM ET
    NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) --  TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the fourth quarter and year ended December 31, 2023, along with recent company developments.
  • Cash Position and Financial Guidance: Cash, cash equivalents and investment securities were $217.5 million as of December 31, 2023.
  • The Company will host a conference call today, February 28, 2024, at 8:30 AM ET, to discuss the Company’s financial results from the fourth quarter and full year ended December 31, 2023.
  • To participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics.

TG Therapeutics Announces Issuance of Additional Patents for BRIUMVI® (ublituximab-xiiy)

Retrieved on: 
Tuesday, February 27, 2024

NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (TG) today announced the issuance of three additional patents by the United States Patent and Trademark Office (USPTO) for BRIUMVI® (ublituximab-xiiy), the first and only anti-CD20 monoclonal antibody approved in the US for patients with relapsing forms of multiple sclerosis (RMS) that can be administered in a one-hour infusion following the starting dose.

Key Points: 
  • NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (TG) today announced the issuance of three additional patents by the United States Patent and Trademark Office (USPTO) for BRIUMVI® (ublituximab-xiiy), the first and only anti-CD20 monoclonal antibody approved in the US for patients with relapsing forms of multiple sclerosis (RMS) that can be administered in a one-hour infusion following the starting dose.
  • The additional recently issued patents, US Patent Nos.
  • 11,807,689; 11,814,439; and 11,884,740, leverage the unique glycoprofile of ublituximab to extend patent protection covering the composition of matter of ublituximab and methods of treatment utilizing ublituximab into 2042.
  • Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics, stated, “We are pleased to announce the issuance of these additional patents for BRIUMVI which add to our existing patent portfolio, and extend patent protection through 2042.

FLYR Hospitality and RateGain Enter Technology Partnership

Retrieved on: 
Tuesday, February 27, 2024

LOS ANGELES, Feb. 27, 2024 (GLOBE NEWSWIRE) -- FLYR , the AI-powered travel technology platform, today announced a partnership with RateGain (NSE: RATEGAIN | BSE: 543417) Travel Technologies Limited (RateGain), a global provider of SaaS solutions for travel and hospitality.

Key Points: 
  • LOS ANGELES, Feb. 27, 2024 (GLOBE NEWSWIRE) -- FLYR , the AI-powered travel technology platform, today announced a partnership with RateGain (NSE: RATEGAIN | BSE: 543417) Travel Technologies Limited (RateGain), a global provider of SaaS solutions for travel and hospitality.
  • The partnership will bring together FLYR’s AI-powered Revenue Optimization System (RMS) with RateGain’s industry-leading channel management and distribution solutions to help hotels improve their revenue.
  • Together, FLYR and RateGain will help the world’s leading hotels improve their businesses – delivering a seamless integration for revenue management.
  • This collaboration reinforces both companies' commitment to delivering solutions that drive success for the hospitality industry.

TG Therapeutics Announces European Launch of BRIUMVI® (ublituximab-xiiy)

Retrieved on: 
Monday, February 26, 2024

The launch commenced in Germany, with additional launches throughout Europe to follow.

Key Points: 
  • The launch commenced in Germany, with additional launches throughout Europe to follow.
  • In accordance with the ex-US commercialization agreement, TG Therapeutics will receive a milestone payment of $12.5 million for the first launch of BRIUMVI in a European country.
  • Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics, stated, “We want to congratulate our partner, Neuraxpharm, on the official launch of BRIUMVI in Europe.
  • TG Therapeutics entered into an agreement with Neuraxpharm (the commercialization agreement) for the ex-US commercialization of BRIUMVI® in August 2023.

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

Retrieved on: 
Tuesday, February 20, 2024

NEW YORK, Feb. 20, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, being held February 29 – March 2, 2024, in West Palm Beach, Florida.

Key Points: 
  • NEW YORK, Feb. 20, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, being held February 29 – March 2, 2024, in West Palm Beach, Florida.
  • Abstracts are now available online and can be accessed on the ACTRIMS meeting website at www.forum.actrims.org .
  • Details of the upcoming presentations are outlined below.
  • Lead Author: Barry Singer, MD, The MS Center for Innovations in Care - Missouri Baptist Medical Center, St. Louis, MO
    Following the presentations, the data presented will be available on the Publications page, located within the Pipeline section, of the Company’s website at www.tgtherapeutics.com/publications.cfm .

Tracker RMS Expands Recruitment Technology Offering into the Australia and New Zealand Markets

Retrieved on: 
Wednesday, March 6, 2024

Tracker RMS , a leading provider of recruitment software solutions, today announced its expansion into the Australia and New Zealand (ANZ) markets.

Key Points: 
  • Tracker RMS , a leading provider of recruitment software solutions, today announced its expansion into the Australia and New Zealand (ANZ) markets.
  • This strategic move comes with the appointment of Brian Hill as general manager for the ANZ region, bringing to the role more than two decades of experience in the recruitment industry.
  • From large, blue-collar agencies to startup ventures in permanent recruitment, Tracker offers tailored solutions to meet the diverse needs of recruiters across the globe.
  • Tracker CEO Andy Jones added: “Brian’s extensive experience and leadership skills make him the perfect candidate to drive our growth in the ANZ region.

NASA’s Jet Propulsion Laboratory Enhances Public Safety with CentralSquare Technologies' Pro Suite

Retrieved on: 
Tuesday, March 5, 2024

CentralSquare Technologies , an industry leader in public sector technology, today announced that NASA's Jet Propulsion Laboratory (JPL), a federally funded research and development center (FFRDC) funded by NASA, has selected CentralSquare Technologies’ Public Safety Pro Suite to replace Caliber Public Safety and Motorola Solutions.

Key Points: 
  • CentralSquare Technologies , an industry leader in public sector technology, today announced that NASA's Jet Propulsion Laboratory (JPL), a federally funded research and development center (FFRDC) funded by NASA, has selected CentralSquare Technologies’ Public Safety Pro Suite to replace Caliber Public Safety and Motorola Solutions.
  • NASA JPL will upgrade its campus safety technology to the Pro Suite , including new Computer Aided Dispatch (CAD), Record Management System (RMS), 911 and Mobile solutions.
  • With CentralSquare Pro Suite, NASA JPL gains advanced capabilities for in-office and field operations.
  • "Within the Pro Suite our connected CAD system can streamline queries, while our mobile functionality enables instant access to calls, all while maintaining critical security."